Faculty Council
Intellectual Property Committee Report

Craig M. Lilly, MD, Chair
University of Massachusetts Chan Medical School Intellectual Property Committee

December 7, 2023
2023 Areas of Focus

1. To increase faculty awareness of the available intellectual property development resources provided by the University.

2. To review the programs of the Office of Innovation and Business Development and provide our business development leadership with actionable feedback to maximize the use and utility of these valuable resources.

3. To solicit and review faculty concerns related to intellectual property and work through Dr. Fitzgerald to communicate validated and significant issues to our senior leaders.
2023 Committee Membership

• Voting Members: Craig M. Lilly MD (chair), Christian Klaucke MD, Elaine Lim, PhD, Xiang Yang, PhD, and Wen Xue PhD, Rodger Davis PhD, and Andrew Fischer MD

• Alternate members: Thoru Pederson PhD., Shan Lu MD, Patrick Emery PhD, Glen Raffel MD, PhD, and Michael Spink DDS, MD (Baystate).

• Non-Voting Members: Patricial Wynne PhD, MBA, John Lindstedt CPA, Kate Fitzgerald PhD.
Office of Innovation & Business Development

Support for Innovators

— Identify and Protect Proprietary Innovations

— Provide Guidance and Support to Faculty and Staff regarding the Commercialization of their Inventions

— Collaborate with Academic and Commercial Partners to Further Emerging Technologies through the use of Material Transfer, Confidential Disclosure, Inter-Institutional, Sponsored Research, Option and License Agreements

— Ensure the Mandatory Reporting of Federally Funded Inventions to Maintain Government Compliance

— Introduce Faculty and Staff to Potential Investment Partners
Disclose to BRIDGE now and to others at the best time

- The USPTO now determines inventorship using a first-to-file system rather than a first-to-invent system
- BRIDGE engagement starts with an Invention Disclosure form that launches the commercialization process.
Activity in FY23

- Invention Disclosures: 80
- Total Issued Patents: 78
- CDAs: 195
- MTAs: 226
- Licenses/Options: 26
- SRAs: 22
- License/Option Revenue: $29M
- Total SRA Value: $12M
Approved Products

- CLARINEX (desloratadine)
- onpattro (patisiran) lipid complex injection 10 mg/5 mL
- SPINRAZA (nusinersen) injection 12 mg/5 mL
- ZINPLAVA (bezlotoxumab) Injection 25 mg/mL
- SYNAGIS® PALIVIZUMAB
- CYTOGAM® Cytomegalovirus Immune Globulin Intravenous (Human) (CMV-IVIG)

23 June 1960
Enovid, world’s first oral contraceptive, approved.
Innovator Resources and Concerns

Innovators have found the translational and device development resources of the University including our CTSA, CAPCaT, and M2D2 programs to be helpful.

There have been no faculty concerns identified in 2023 that required communication with our senior leadership.